The text below is for information purposes only. Please consult your own medical professional.
ALL WEIGHT LOSS MEDICATION DESCRIBED BELOW ARE TO BE USED IN CONJUNCTION WITH BETTER/HEALTHIER FOOD CHOICES, DAILY PURPOSEFUL MOVEMENT/EXERCISE, REDUCE STRESS, GET QUALITY SLEEP, AND ADEQUATELY HYDRATE.
In other words, the patient must make moderate to robust lifestyle changes and habits while taking these medications for better and more sustained overall lifelong health.
What is GLP-1?
GLP-1 is a hormone that is produced by cells in the intestine in response to food intake. It stimulates insulin secretion by the pancreas, which helps to lower blood sugar levels. GLP-1 also suppresses the release of glucagon, which is a hormone that raises blood sugar levels.
Semaglutide is a GLP-1 agonist and the active ingredient in the brand name drugs Ozempic and Wegovy. More on these two brand name weight loss medications below.
What is GIP?
GIP is produced by cells in the small intestine and is released in response to the presence of nutrients, particularly fat and glucose. It stimulates insulin secretion by the pancreas, which helps to lower blood sugar levels. However, unlike GLP-1, GIP does not suppress the release of glucagon.
Trizepatide is BOTH a GLP-1 and GIP. Trizepatide is the active ingredient in the brand name drug Mounjaro.
Ozempic, Mounjaro, Wegovy
These are the brand names give by the drug manufacturers currently on the market for purchase at your local pharmacy.
All 3 of these medications have the active ingredient Semaglutide (Ozempic or Wegovy) or Trizepatide (Mounjaro).
More weight loss medications are currently in clinical trials and will be coming to market sometime in late 2023 or 2024.
21 day Keto & Fasting Jump Start Program
If you’re new to low carb and fasting you may need someone like me to hold you accountable. I have a one on one program. Click on this link for The Kellie Kitchen Keto Accountability Coaching Program.
I’ll teach you how to eat delicious food and still lose weight, look great and feel AMAZING.
The DIY Keto WorkBook
However, if you’re a “Do It Yourself” kind of person I have created a workbook to take you through the 21 day Jump Start Journey.
Click HERE find the 21 day Keto Guide Workbook on Amazon…
You can find the downloadable Keto workbook version at a discount here…
Weight Loss Medication: SEMAGLUTIDE
WEEKLY: Injectable brand name is Ozempic (FDA approved for type 2 diabetes)
WEEKLY: injectable brand name is Wegovy (FDA approved for chronic weight management in adults with obesity or over weight with at least 1 weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol)
DAILY: Oral brand name is Rybelsus (FDA approved for Type 2 diabetes)
Semaglutide is a GLP-1 agonist created for Type 2 Diabetes and FDA approved under the brand name Ozempic in 2019. It was approved for the indication of weight loss under the brand name Wegovy in June 2021.
GLP-1 works to increase insulin levels by activating cells in the pancreas. It also triggers hormone release to delay the emptying of the stomach, sometimes causing nausea.
Studies suggest that daily ORAL semaglutide should be taken as an add-on therapy to metformin AND moderate to robust lifestyle changes to diet and exercise. Daily oral semaglutide is provided as an option for those that are unable or unwilling to self-administer injectables.
Notes on Semaglutide
AVOID WHEN: History of Thyroid C-cell tumors; Pregnant; Breastfeeding; Trying to conceive; History of anorexia/bulimia
SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)
EXPECTED RESULTS: When used alongside moderate to robust lifestyle management (200 min exercise/week, healthier diet, bimonthly nutritionist visits) patients observed 10-14% weight loss, maintained over 2 years.
Synopsis and potential benefits…
Semaglutide is a prescription weight loss medication that belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) agonists. It is primarily used to treat type 2 diabetes. However, it has also been shown to be effective in promoting weight loss.
- Promotes weight loss: In clinical trials, semaglutide has been shown to be effective in helping people lose weight. In one study, people taking semaglutide lost an average of about 11% of their body weight, compared to about 3% in the placebo group.
- Improves blood sugar control: By helping to lower blood sugar levels, semaglutide may also help improve blood sugar control in people with type 2 diabetes.
- May improve other health markers: In addition to weight loss and blood sugar control, semaglutide may also improve other health markers such as blood pressure, cholesterol levels, and markers of inflammation.
- Can be taken as a once-weekly injection: Semaglutide is taken as a once-weekly injection, which may be more convenient for some people compared to taking a daily pill.
It’s important to note that semaglutide is a prescription weight loss medication and should be used under the supervision of a healthcare provider. Your healthcare provider will be able to determine if semaglutide is appropriate for you and help you determine the best dosage and treatment plan.
LIRAGLUTIDE
DAILY Injectable brand names Saxenda or Victoza (FDA approved for weight loss)
Liraglutide is a GLP-1 agonist weight loss medication, very similar to Semaglutide. It was initially developed as a medication for Type 2 Diabetes, however it also helps patients with weight loss. By activating GLP-1 receptors, this medication works to slow the rate at which your stomach empties, and to send signals to your brain to decrease appetite.
GLP-1 works to increase insulin levels by activating cells in the pancreas. It also triggers hormone release to delay the emptying of the stomach, sometimes causing nausea.
Notes on Liraglutide
AVOID WHEN: Pancreatitis Gallstones; Family history of Thyroid Cancer; Thyroid disorders
SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)
EXPECTED RESULTS:
The SCALE Trial showed patients can lose 6.2% over 52 weeks in conjunction with a daily 500 calorie deficit and increased walking (CI 7.5 to 4.6%).
Weight Loss Medication: TRIZEPATIDE
WEEKLY Injectable brand name is Mounjaro.
Tirzepatide is the newest form of weight loss medication weekly injectible. It was recently approved for Type 2 diabetes and works through BOTH the GLP-1 receptor AND GIP receptors. BOTH GLP-1 and GIP receptors work to slow stomach emptying and decrease appetite.
Both GLP-1 and GIP receptors work to decrease the rate your stomach empties– keeping you full for longer. They also work to decrease your appetite and cravings. However, this weight loss medication is meant to work in conjunction with a healthier diet and moderate/purposeful daily exercise for long term maintenance.
Notes on Trizepatide
AVOID WHEN: Chronic malabsorption; Pregnancy; Cholestasis/History of Gallbladder disease; Pancreatitis; Family history of Thyroid Cancer; Thyroid disorders
SIDE EFFECTS: Nausea (44%); Vomiting (25%); Diarrhea/GI distress (30%)
EXPECTED RESULTS:
The SURMOUNT-1 trial showed expected weight loss of 22.5%. Additional trials have shown this medication in conjunction with a healthier diet and moderate/purposeful exercise is TWICE as effective as Semaglutide 1.0mg.
AMG 133
NOT ON THE MARKET YET…STILL IN PHASE 1 CLINICAL TRIALS. Showing the most promise, but it’s still early.
MONTHLY injectable, no brand name indicated. Most like Trizepatide but administered MONTHLY.
AMG 133 is a bispecific glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and glucagon-like peptide-1 (GLP-1) receptor agonist molecule. AMG 133 mimics the agonist effects of GLP-1 and antagonizes the effects of glucose-dependent insulinotropic polypeptide (GIP).
Difference between GLP-1 and GIP…
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are both hormones that play a role in glucose metabolism and insulin secretion. However, they have different effects on the body and are produced by different cells.
GLP-1 is a hormone that is produced by cells in the intestine in response to food intake. It stimulates insulin secretion by the pancreas, which helps to lower blood sugar levels. GLP-1 also suppresses the release of glucagon, which is a hormone that raises blood sugar levels.
GIP
GIP is produced by cells in the small intestine and is released in response to the presence of nutrients, particularly fat and glucose. It stimulates insulin secretion by the pancreas, which helps to lower blood sugar levels. However, unlike GLP-1, GIP does not suppress the release of glucagon.
In summary, both GLP-1 and GIP stimulate insulin secretion and help to lower blood sugar levels, but they have different effects on the release of glucagon. GLP-1 suppresses the release of glucagon, while GIP does not.
Talk to your Doctor
None of the information above regarding weight loss medication is meant to treat or suggest treatment plan for obesity, Type 2 Diabetes, or any other other issue. However, this information provided is simply a compilation of research done on this subject.